Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
544
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
stocks
Vegemite owner’s shares remain expensive on normalising profits.
stocks
Ask the analyst: Where does GYG stand following its US exit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,051.10 | 25.30 | 0.28% |
| CAC 40 | 8,508.07 | 33.21 | 0.39% |
| DAX 40 | 25,779.31 | 198.43 | 0.78% |
| Dow JONES (US) | 52,900.07 | 594.83 | 1.14% |
| FTSE 100 | 10,679.03 | 26.16 | 0.25% |
| HKSE | 23,638.24 | 288.21 | 1.23% |
| NASDAQ | 25,832.67 | 207.36 | -0.80% |
| Nikkei 225 | 69,081.46 | 662.61 | -0.95% |
| NZX 50 Index | 13,697.07 | 78.65 | 0.58% |
| S&P 500 | 7,483.24 | 0.01 | 0.00% |
| S&P/ASX 200 | 8,846.20 | 27.90 | 0.32% |
| SSE Composite Index | 4,032.17 | 11.47 | -0.28% |